Papatheodoridi M. Rates and predictors of HBsAg loss after discontinuation of effective long-term Entecavir or Tenofovir therapy in non-cirrhotic HBeAg-negative Chronic Hepatitis B patients: Results from the DARING-B prospective Greek study. PS-159.
Booster met zelfde of ander type vaccin tegen COVID-19 is effectief
jun 2022 | Vaccinatie, Virale infecties